Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,796 total articles
Vera Therapeutics, a US-based commercial-stage biotech company specializing in autoimmune kidney diseases, will present at the Cantor Global Healthcare Conference and the Morgan Stanley Global Healthcare Conference in September 2026. The company's management aims to engage investors through fireside chats and one-on-one meetings, highlighting their…
Alumis announced that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus (SLE) did not meet primary and secondary endpoints in the overall population. However, robust responses in the prespecified interferon gene signature-high (IFNGS-high) subgroup, representing most moderate-to-severe SLE cases, support …
KANZHUN LIMITED, a leading Chinese online recruitment platform, announced the rotation of its president position effective September 1, 2026. Mr. Xu Chen steps down as president but remains as executive director and Chief Marketing Officer, while Mr. Tao Zhang takes over as rotating president alongside his roles as executive director and Chief Tech…
BridgeBio Pharma, a biopharmaceutical company focused on genetic condition medicines, announced that its management will participate in several upcoming healthcare investor conferences in September 2026. These include Wells Fargo, Cantor Global, Morgan Stanley, and Bernstein Insights conferences. The company aims to communicate its developments and…
Ardelyx Inc., a US commercial-stage biopharmaceutical company, has announced its participation in several major investor conferences in New York during September 2026, including Citi, Cantor, and Morgan Stanley healthcare events. The company will host fireside chats and investor meetings, providing updates on its commercial products IBSRELA and XPH…
Streamex Corp., a Nasdaq-listed technology company specializing in tokenization of commodity assets, appointed Laura Kiernan as Head of Investor Relations. Kiernan brings over 30 years of capital markets experience to lead investor relations strategy, aiming to bridge the value of Streamex's platform with market perception. The move supports Stream…
FocalTherics, a leader in robotic focal therapy, announced that its CEO and CFO will present and host investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15-16, 2026. The company focuses on minimally invasive medical devices leveraging proprietary focused ultrasound technology to treat various …
Telesat Government Solutions, a US-based subsidiary of Telesat Corporation (TSAT), has signed a strategic collaboration with Cailabs US, Inc. to integrate secure, resilient, high-capacity optical space-to-ground connectivity for U.S. Government and allied missions. The partnership aims to combine Telesat's Lightspeed LEO satellite network with Cail…
USBC, a publicly traded technology company focused on tokenized deposits, announced the hiring of Richa Pareek as Chief Product Officer. Pareek brings extensive experience from JPMorgan Chase, Coinbase, and other leading tech firms. Her appointment coincides with the next phase of USBC's product testing and platform development for their blockchain…
Comstock Resources announced a strategic partnership with SOCAR involving the sale of non-operated interests in its Legacy and Western Haynesville assets and Pinnacle Gas Services for $1.65 billion in cash. Additionally, Comstock entered a $450 million drilling joint venture with majority stockholder Jerry Jones to fund drilling of Haynesville well…
Stoke Therapeutics and Biogen presented 4-year clinical data showing sustained improvements in cognition, behavior, and durable seizure reductions with a generally well-tolerated safety profile for zorevunersen, an investigational antisense oligonucleotide targeting the underlying cause of Dravet syndrome. The ongoing global Phase 3 EMPEROR study a…
Kura Oncology, Inc., a biopharmaceutical company specializing in precision cancer medicines, announced that its management will present at three prominent healthcare investor conferences in September 2026. The events include the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference. …
Descartes Systems Group announced it has acquired Extensiv, enhancing its warehouse management and omnichannel fulfillment solutions for third-party logistics providers (3PLs) and ecommerce brands. The acquisition strengthens Descartes' Global Logistics Network by integrating AI-powered capabilities to optimize inventory, order management, and fulf…
Unicycive Therapeutics, a clinical-stage biotech company focused on developing treatments for kidney diseases, announced its CEO will present at the upcoming H.C. Wainwright Global Investment Conference. The company is advancing novel therapies including oxylanthanum carbonate for hyperphosphatemia in dialysis patients and UNI-494 for acute kidney …
Ocugen has dosed the first patient in its global Phase 3 registrational trial of OCU410, a one-time modifier gene therapy targeting multiple disease pathways for geographic atrophy secondary to dry age-related macular degeneration (dAMD). The therapy has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation, enabling potential acce…
Invivyd, Inc. has appointed Marc W. Elia as CEO, who was previously Chairman and has driven the company's scientific and corporate strategy. The company is nearing the completion of Phase 3 studies (DECLARATION and LIBERTY) for its COVID-19 monoclonal antibody candidate VYD2311, with top-line data expected by end of Q3 2026. Invivyd is preparing re…
Seres Therapeutics, a clinical-stage biotechnology company specializing in live biotherapeutics, announced its participation in the H.C. Wainwright Investment Conference and will provide an overview of its pipeline including SER-155 and SER-603. The company continues to develop treatments targeting oncology-related microbiome therapies and inflamma…
Jade Biosciences, a clinical-stage biotech focused on autoimmune diseases, announced its participation in several upcoming investor conferences, including Wells Fargo, Citi, HC Wainwright, and Stifel events in September 2026. The company will host fireside chats and one-on-one meetings to discuss its pipeline, including lead product candidate JADE1…
Upstream Bio plans to initiate pivotal Phase 3 trials in Q1 2027 for verekitug, a novel TSLP receptor antagonist, in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The trials will evaluate a 400 mg dose administered every 12 weeks versus placebo, targeting broad patient populations. Successful Phase 3 results could lead to FDA…
RedHill Biopharma announced it has acquired exclusive global and U.S. commercialization rights to Ferring Pharmaceuticals' two FDA-approved gastrointestinal drugs, Rebyota and Clenpiq, in a transformative deal secured through proceeds from its prior Talicia divestiture. These drugs collectively generated about $37.5 million in U.S. net sales in 202…
Processa Pharmaceuticals announced participation in two upcoming investor conferences to discuss its lead BTK inhibitor drug candidate VT-7208 and recent acquisition of Vidya Therapeutics. The company completed a $200 million private placement to support development across immune-mediated diseases and plans special shareholder meetings for preferre…
Ocular Therapeutix, a biopharmaceutical company focused on retinal disease treatments, announced its participation in several investor and scientific conferences in September and October 2026. The company will present updated data from its Phase 3 trials of AXPAXLI (OTX-TKI) for wet age-related macular degeneration and share information about its p…
Tilray Brands' BrewDog division has launched 'Liquid Visions', a new premium craft beer series featuring four artist-designed cans and bold hop-forward flavors. This follows multiple awards BrewDog beers received at the 2026 World Beer Awards. The series will be rolled out across major UK grocery chains, including Tesco and Sainsbury's, aiming to r…
Kymera Therapeutics announced the completion of enrollment for its KT-621 BROADEN2 Phase 2b trial in atopic dermatitis (AD), with topline data expected by the end of 2026 and plans to start Phase 3 trials by mid-2027. Additionally, a parallel Phase 2b trial in asthma is ongoing with results anticipated in late 2027. KT-621 is a first-in-class oral …
Aquestive Therapeutics, a pharmaceutical company specializing in innovative drug delivery technologies, will participate in four investor conferences in September 2026 to present its business updates and development programs. The company highlighted its proprietary products including Anaphylm sublingual film and AQST-108 topical gel, and will provi…
